IRIS Accounts Production v24.1.9.2 11651431 Board of Directors 1.11.22 31.10.23 31.10.23 false true false false true false Ordinary 1.00000 152691 144862 213283 107741 122728 99912 243246 152691 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh116514312022-10-31116514312023-10-31116514312022-11-012023-10-31116514312021-10-31116514312021-11-012022-10-31116514312022-10-3111651431ns15:EnglandWales2022-11-012023-10-3111651431ns14:PoundSterling2022-11-012023-10-3111651431ns10:Director12022-11-012023-10-3111651431ns10:PrivateLimitedCompanyLtd2022-11-012023-10-3111651431ns10:SmallEntities2022-11-012023-10-3111651431ns10:AuditExempt-NoAccountantsReport2022-11-012023-10-3111651431ns10:SmallCompaniesRegimeForDirectorsReport2022-11-012023-10-3111651431ns10:SmallCompaniesRegimeForAccounts2022-11-012023-10-3111651431ns10:FullAccounts2022-11-012023-10-3111651431ns10:OrdinaryShareClass12022-11-012023-10-311165143142ns10:Director22022-10-311165143142ns10:Director22021-10-311165143142ns10:Director22022-11-012023-10-311165143142ns10:Director22021-11-012022-10-311165143142ns10:Director22023-10-311165143142ns10:Director22022-10-3111651431ns10:Director22022-11-012023-10-3111651431ns10:RegisteredOffice2022-11-012023-10-3111651431ns5:CurrentFinancialInstruments2023-10-3111651431ns5:CurrentFinancialInstruments2022-10-3111651431ns5:Non-currentFinancialInstruments2023-10-3111651431ns5:Non-currentFinancialInstruments2022-10-3111651431ns5:ShareCapital2023-10-3111651431ns5:ShareCapital2022-10-3111651431ns5:RetainedEarningsAccumulatedLosses2023-10-3111651431ns5:RetainedEarningsAccumulatedLosses2022-10-3111651431ns5:PlantMachinery2022-11-012023-10-3111651431ns5:PlantMachinery2023-10-3111651431ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-10-3111651431ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-10-3111651431ns10:OrdinaryShareClass12023-10-31116514311ns10:Director12022-10-31116514311ns10:Director12021-10-31116514311ns10:Director12022-11-012023-10-31116514311ns10:Director12021-11-012022-10-31116514311ns10:Director12023-10-31116514311ns10:Director12022-10-31
REGISTERED NUMBER: 11651431 (England and Wales)









SURBITON MEDICS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 OCTOBER 2023






SURBITON MEDICS LIMITED (REGISTERED NUMBER: 11651431)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


SURBITON MEDICS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 OCTOBER 2023







DIRECTORS: Dr S Sripathy
Dr K Sripathy





REGISTERED OFFICE: 22 Blakes Avenue
New Malden
Kingston upon Thames
KT3 6LR





REGISTERED NUMBER: 11651431 (England and Wales)





ACCOUNTANTS: Morris Crocker
Chartered Accountants
Station House
North Street
Havant
Hampshire
PO9 1QU

SURBITON MEDICS LIMITED (REGISTERED NUMBER: 11651431)

BALANCE SHEET
31 OCTOBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,012 -

CURRENT ASSETS
Debtors 5 276,366 184,224
Cash at bank 1,021 9,211
277,387 193,435
CREDITORS
Amounts falling due within one year 6 100,818 62,086
NET CURRENT ASSETS 176,569 131,349
TOTAL ASSETS LESS CURRENT
LIABILITIES

177,581

131,349

CREDITORS
Amounts falling due after more than one
year

7

(42,963

)

(54,298

)

PROVISIONS FOR LIABILITIES (253 ) -
NET ASSETS 134,365 77,051

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 134,265 76,951
SHAREHOLDERS' FUNDS 134,365 77,051

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

SURBITON MEDICS LIMITED (REGISTERED NUMBER: 11651431)

BALANCE SHEET - continued
31 OCTOBER 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 31 July 2024 and were signed on its behalf by:





Dr S Sripathy - Director


SURBITON MEDICS LIMITED (REGISTERED NUMBER: 11651431)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2023

1. STATUTORY INFORMATION

Surbiton Medics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on cost

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties and loans to related parties and investments in non-puttable ordinary shares.

Trade and other debtors
Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment

Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, deposits with banks and other short-term highly liquid investments and bank overdrafts. In the balance sheet, bank overdrafts are shown within borrowings or current liabilities.

Trade and other creditors
Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


SURBITON MEDICS LIMITED (REGISTERED NUMBER: 11651431)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 OCTOBER 2023

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 1,350
At 31 October 2023 1,350
DEPRECIATION
Charge for year 338
At 31 October 2023 338
NET BOOK VALUE
At 31 October 2023 1,012

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 12,527 10,940
Other debtors 263,839 173,284
276,366 184,224

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Taxation and social security 86,801 49,807
Other creditors 14,017 12,279
100,818 62,086

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Other creditors 42,963 54,298

SURBITON MEDICS LIMITED (REGISTERED NUMBER: 11651431)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 OCTOBER 2023

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
100 Ordinary £1 100 100

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 October 2023 and 31 October 2022:

2023 2022
£    £   
Dr S Sripathy and Dr K Sripathy
Balance outstanding at start of year 152,691 144,862
Amounts advanced 213,283 107,741
Amounts repaid (122,728 ) (99,912 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 243,246 152,691